The table below shows Apellis Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$60.97M
-$53.41M
-$132.98M
-$177.62M
-$111.56M
-$153.31M
Capital expenditure
-
$8.00K
$293.00K
$259.00K
$86.00K
$484.00K
Investing cash flow
-
-$8.00K
-$293.00K
-$259.00K
-$271.95M
-$146.76M
Dividends paid
-
-
-
APLS operating cash flow (10-K history)
Apellis Pharmaceuticals, Inc. reported operating cash flow of $45.33M for fiscal year 2025. That is up 151.6% from -$87.87M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$26.00M (FY 2016) to $45.33M. Figures come from the company's audited annual reports as filed with the SEC.